Scholarlink

<p>To analyze dalbavancin’s potential for long-term suppressive therapy in patients with infected ventricular assist devices (VAD), the VAD register of Heidelberg University Hospital was searched for patients who received dalbavancin for long-term suppression therapy. Clinical data, laboratory, and microbiological results were extracted. Healthcare utilization was analyzed by number of hospitalizations before and during dalbavancin therapy with a generalized linear mixed model. Drug safety was investigated with regard to liver and renal function, and thrombocyte count. Thirteen patients were included in the study; receiving a regimen of 1500&#xa0;mg dalbavancin at day 1 and day 8 with repetition of the cycle at day 42. The mean follow-up time was 254&#xa0;days (IQR 252). Eight patients were treated for driveline infection and five patients for driveline and blood stream infection, all of them caused by <i>Staphylococcus aureus</i>. The majority of patients (n = 11/13) underwent surgical wound debridement and intravenous antibiotic therapy before start of dalbavancin. Under dalbavancin therapy, no blood stream infection was observed and significantly fewer hospitalizations occurred with an odds ratio of 0.27 (<i>p</i> &lt; 0.001). In four patients, elevations of liver transaminases were detected and led to discontinuation of dalbavancin therapy in one patient.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Exploratory analysis of long-term suppressive therapy with dalbavancin in ventricular assist device infections caused by Staphylococcus aureus

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月3日

查看全文
  • Benedict Morath,
  • Sabrina Klein,
  • Ute Chiriac,
  • Yvonne Müller,
  • Lisa Koeppel,
  • Otto Frey,
  • Heike Lanzinger,
  • Philipp Schlegel,
  • Sonja Hamed,
  • Dennis Nurjadi,
  • Philipp Ehlermann,
  • Matthias Karck,
  • Anna L. Meyer

摘要

To analyze dalbavancin’s potential for long-term suppressive therapy in patients with infected ventricular assist devices (VAD), the VAD register of Heidelberg University Hospital was searched for patients who received dalbavancin for long-term suppression therapy. Clinical data, laboratory, and microbiological results were extracted. Healthcare utilization was analyzed by number of hospitalizations before and during dalbavancin therapy with a generalized linear mixed model. Drug safety was investigated with regard to liver and renal function, and thrombocyte count. Thirteen patients were included in the study; receiving a regimen of 1500 mg dalbavancin at day 1 and day 8 with repetition of the cycle at day 42. The mean follow-up time was 254 days (IQR 252). Eight patients were treated for driveline infection and five patients for driveline and blood stream infection, all of them caused by Staphylococcus aureus. The majority of patients (n = 11/13) underwent surgical wound debridement and intravenous antibiotic therapy before start of dalbavancin. Under dalbavancin therapy, no blood stream infection was observed and significantly fewer hospitalizations occurred with an odds ratio of 0.27 (p < 0.001). In four patients, elevations of liver transaminases were detected and led to discontinuation of dalbavancin therapy in one patient.